NIAID Launches Program to Improve Medical Tools Against Emerging Infectious Diseases [Primary member]
submitted by kickingbird at Nov, 2, 2004 from NIAID
WASHINGTON, Nov. 1, 2004 - The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded 14 contracts totaling more than $73 million to ... Medimmune:Flu-spray firm runs high risks [Primary member]
submitted by kickingbird at Nov, 1, 2004 from The New York Times
It would seem a drug executive´s dream come true. On Oct. 21, the secretary of health and human services in the United States summoned top executives of MedImmune to his office in Washington to seek ... Binax Announces FDA 510k Clearance of NOW Influenza A & B Rapid Test for Identification and Differentiation between Flu A and Flu B on One Simple Test [Primary member]
submitted by kickingbird at Oct, 29, 2004 from BUSINESS WIRE
Oct. 28, 2004--Binax, Inc., a leading developer of rapid diagnostic tests, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the NOW(R) Influenza A & B test. ... Protein Sciences Announces FDA Clearance to Conduct Proof of Principle/Field Trial of FluBlok(TM), its Cell-Culture Influenza Vaccine [Primary member]
submitted by kickingbird at Oct, 29, 2004 from Protein Sciences Corporation (via http://biz.yahoo.com/prnews/041028/nyth151_1.html)
Protein Sciences Corporation, a world leader in developing the next generation of human and veterinary vaccines, announced today that it had received FDA clearance to conduct a Phase II/III proof of principle/field ... Biota Fundraising Indicates Stockholders Support for Suit Against GSK [Primary member]
submitted by kickingbird at Oct, 29, 2004 from Biota Holdings Limited (via http://biz.yahoo.com/prnews/041028/lath129_1.html)
The funds were raised under a ´Share Purchase Plan´ (SPP), which allows Australian listed companies to offer their local stockholders the annual opportunity to buy shares up to a value of A$5,000 ... Quidel Reports Third Quarter Financial Results [Primary member]
submitted by kickingbird at Oct, 28, 2004 from businesswire
Oct. 27, 2004--Quidel Corporation (NASDAQ:QDEL), a leading provider of rapid point-of-care diagnostic tests, today reported financial results for the third quarter and nine months ended September ... USDA Awards Avian Influenza Vaccine Contract to Fort Dodge Animal Health [Primary member]
submitted by kickingbird at Oct, 27, 2004 from Animal and Plant Health Inspection Service
The U.S. Department of Agriculture's Animal and Plant Health Inspection Service, Center for Veterinary Biologics, has awarded a five-year contract to Fort Dodge Animal Health to develop an avian influenza ... MedImmune expands production plans for FluMist [Primary member]
submitted by kickingbird at Oct, 26, 2004 from pharmabiz.com (via http://www.pharmabiz.com/article/detnews.asp?articleid=24311)
MedImmune Inc is increasing its planned delivery of FluMist (Influenza Virus Vaccine Live, Intranasal) up to a total of three million doses. Originally the company had completed production of 1.1 million ... Quidel Launches flutest.com; Interactive Web Site Delivers Practical Flu Solutions For Consumers [Primary member]
submitted by kickingbird at Oct, 22, 2004 from businesswire
SAN DIEGO--(BUSINESS WIRE)--Oct. 21, 2004--Quidel Corporation (Nasdaq:QDEL), a leading provider of rapid point-of-care diagnostic tests, today announced the launch of http://flutest.com -- a Web site dedicated ... MedImmune Initiates Phase III Clinical Trial Comparing Intranasal Influenza Vaccine With Injectable Flu Vaccine
submitted by kickingbird at Oct, 22, 2004 from Dow Jones Newswires (via http://www.biospace.com/news_story.cfm?StoryID=17774620&)
MedImmune, Inc. announced today that it has initiated a pivotal head-to-head Phase 3 clinical trial designed to compare its next-generation, refrigerator- stable intranasal influenza vaccine (CAIV-T: cold ... GSK may boost its flu drug [Primary member]
submitted by kickingbird at Oct, 21, 2004 from The News & Observer Publishing Company (via http://newsobserver.com/business/story/1752114p-8029150c.htm)
With the nation丩s supply of flu vaccine in short supply, GlaxoSmithKline is exploring ways to increase the availability of Relenza, an anti-flu medication taken to fight the disease. But the giant drugmaker ... EU mission to decide on lifting poultry ban
submitted by kickingbird at Oct, 19, 2004 from XinhuaNet News (via http://news.xinhuanet.com/english/2004-10/19/content_2108263)
BEIJING, Oct. 19 (Xinhuanet) -- A visit by European Union officials next week will decide whether a ban on Chinese poultry products should be lifted.
A few days ago the EU formally ... Few companies willing to make flu vaccines
submitted by kickingbird at Oct, 17, 2004 from The Washington Post
Few companies willing to make flu vaccinesUnprofitable: The shortage of shots exposes a troubling industrywide trendWyeth Pharmaceuticals doesn磘 make flu shots anymore, and it doesn磘 miss them one bit. For ... China to promote farming export [Primary member]
submitted by kickingbird at Oct, 16, 2004 from Xinhua News Agency (via http://news.xinhuanet.com/english/2004-10/16/content_2096412)
GUANGZHOU, Oct. 15 (Xinhuanet) -- The expansion of farming products export will be a major target in China's foreign trade development in the future, said Vice-Minister of Commerce Yu Guangzhou Friday ... No chance of Chiron vaccine, U.S. says [Primary member]
submitted by kickingbird at Oct, 16, 2004 from Reuters
None of Chiron Corp.'s flu vaccine made at a British plant is safe, which means the U.S. flu vaccine supply will be half of what was expected, U.S. health officials said on Friday.
Federal and state ... Chiron Responds to FDA Announcement; Company Committed to Taking Appropriate Action to Return to Market as Reliable Supplier of Influenza Vaccine [Primary member]
submitted by kickingbird at Oct, 16, 2004 from Business Wire
Chiron Corporation (Nasdaq:CHIR) provided the following statement in response to the announcement by U.S. health officials today.
Chiron profoundly regrets that it is unable to meet the public health ... Quidel Third Quarter 2004 Results Conference Call Alert [Primary member]
submitted by kickingbird at Oct, 15, 2004 from Business Wire
SAN DIEGO--(BUSINESS WIRE)--Oct. 14, 2004--Quidel Corporation (Nasdaq:QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, will release third quarter 2004 financial results after market ... Roche Reports Third Quarter Sales Are Up 9 Percent [Primary member]
submitted by kickingbird at Oct, 15, 2004 from AP
Swiss pharmaceutical giant Roche Group on Thursday announced third-quarter sales up 9 percent from the same period last year, driven by strong growth from its two leading cancer treatments. Sales for the ... A booster shot for vaccine development [Primary member]
submitted by kickingbird at Oct, 15, 2004 from Scripps Howard News Service
Every year in this country influenza kills tens of thousands and requires the hospitalization of about a quarter-million. In epidemic years, the numbers can be astronomical, even when there is enough ... Canadian producer in talks with US over sale of excess flu vaccine [Primary member]
submitted by kickingbird at Oct, 13, 2004 from Canadian Press
U.S. health authorities seeking desperately to overcome a massive shortage of flu vaccine in that country are in discussions with Canada's major influenza vaccine producer, the company confirmed Tuesday. ... 144 items, 20/Page, Page[6/8][|<<] [|<] [1] [2] [3] [4] [5] [6] [7] [8] [>|] [>>|] Search local
Northen China: Beijing - Gansu -
Hebei -
Heilongjiang -
Henan -
Hubei -
Inner mongolia -
Jilin -
Liaoning -
Ningxia -
Qinghai -
Shaanxi -
Shandong -
Shanxi -
Tianjin -
Xinjiang -
Xizang(Tibet)
Southen China: Anhui -
Chongqing -
Fujian -
Guangdong -
Guangxi -
Guizhou -
Hainan -
Hongkong -
Hunan -
Jiangsu -
Jiangxi -
Macao -
Shanghai -
Sichuan -
Taiwan -
Yunnan -
Zhejiang
|
- 
